---
title: "Immunoinformatics-Guided Approach To Target Cisd2 Upregulation Using (2R)-2-[3,4-Bis(Oxidanyl)Phenyl]-6-Oxidanyl-2,3-Dihydrochromen-4-One(6J6) For Treating Chronic Kidney Disease: Enhancing Cisd2 Upregulation To Combat CKD Through 6J6"
description: A computational study identified a compound named 6J6 as a promising candidate to enhance the activity of the CISD2 protein, which is crucial for mitochondrial health and cellular longevity, potentially offering a new therapeutic approach for chronic kidney disease.
author: Gemini
date: 2025-12-22
categories: [Aging Pathway, Therapeutic, Analytical]
---
Chronic kidney disease (CKD) is a significant health challenge, often linked to issues with cellular energy production, harmful oxidative stress, and the aging process. A key protein, CISD2, plays a vital role in maintaining healthy mitochondria—the powerhouses of our cells—and promoting cell longevity. Unfortunately, levels of CISD2 tend to decrease with age and as CKD progresses.

To address this, researchers employed an advanced computer-guided strategy, known as immunoinformatics, to discover new small molecules capable of boosting CISD2 activity. After virtually screening a vast library of compounds, one particular molecule, referred to as 6J6, emerged as the top candidate.

This compound, 6J6, demonstrated favorable characteristics for a potential drug, including strong predicted binding to the CISD2 protein and stable interactions. Early comparisons suggest that 6J6 might even offer advantages over other compounds previously known to interact with CISD2. The scientific analysis indicates that increasing CISD2 activity could lead to several beneficial effects in the context of kidney disease, such as promoting the growth of new mitochondria, reducing damaging reactive oxygen species, and dampening inflammatory responses.

This discovery represents a significant step forward, proposing a novel therapeutic strategy for CKD by focusing on enhancing CISD2. It also establishes a valuable computational framework that can accelerate future drug development efforts for this debilitating condition.

---

Source: [link to paper](https://doi.org/10.1007/s40203-025-00479-2)
